Glutamine antagonists may KEAP lung cancer in check.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 38536918.
- Also identified by DOI 10.1126/sciadv.ado7808 and PMC identifier 10971402.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The glutamine antagonist DRP-104 blocks purine synthesis and combines with checkpoint inhibitors to promote antitumor immunity in KEAP1/NRF2-mutant lung cancers.
Medical subject headings
- Lung Neoplasms